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Background: To analyze the influence of the prothrombotic gene mutation factor V G1691A (factor V
Leiden) and prothrombin G20210A on the risk of a first episode of catheter-related deep venous thrombosis
(DVT) in a group of patients with breast cancer treated with chemotherapy.
Patients and methods: Between January 1999 and February 2001, the occurrence of a first symptomatic
DVT was investigated in a cohort of 300 consecutive patients with locally advanced or metastatic breast cancer
treated at a single institution with fluorouracil-based chemotherapy, administered continuously through a totally
implanted access port. A nested case–control study included 25 women (cases) with catheter-related DVT and
50 controls without DVT matched with cases for age, identical chemotherapy, stage of disease and prognostic
features. The G1691A factor V and G20210A prothrombin mutation genotypes were analyzed.
Results: Five cases [20%; 95% confidence interval (CI) 9% to 39%)] and two controls (4%; 95% CI 1% to
14%) were heterozygous carriers of G1691A factor V (P = 0.04). The age-adjusted odds ratio for catheter-
related DVT was 6.1 (95% CI 1.1–34.3). Only one patient (case) had the G20210A prothrombin gene mutation.
Time from start of chemotherapy infusion to DVT was not significantly different between patients with (median
31 days) and without (median 43 days) G1691A factor V mutation (P = 0.6).
Conclusions: Factor V Leiden carriers with locally advanced or metastatic breast cancer have an increased
risk of developing catheter-related DVT during chemotherapy.
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Introduction
In patients with cancer, the increasing use of dose-intensive and
continuous infusion chemotherapy based upon fluorouracil requires
reliable, long-term central venous catheters (CVC) for both blood
sampling and drug administration. Another reason for the implant
of durable CVC is the increasing application of supportive care
measures, such as intravenous antiemetics, analgesics, antibiotics
and parenteral nutrition [1]. One of the major complications of
CVC is thrombosis of the subclavian vein and, in approximately
one-third of deep venous thrombosis (DVT) cases, pulmonary
embolism [2–4]. In cancer patients, activation of the coagulation
pathway favors venous thromboembolism (VTE), which is the
second leading cause of death in these patients [5–7]. Even though
the association between cancer and hypercoagulability is well
established, the pathogenesis of VTE in these patients has not been
entirely elucidated. While coagulation activation is encountered in
up to 90% of cancer patients, only 4–15% of them develop DVT
or pulmonary embolism [8]. Chemotherapy increases the risk of
VTE by damaging the vascular endothelium and decreasing
plasma levels of naturally occurring coagulation inhibitors [9].
The highest incidence of VTE occurs during advanced disease,
being influenced by larger cancer cell burden, immobilization for
pathologic bone fractures, immobilization due to tumor cachexia
and mechanical compression of the veins by tumor mass [10].
Even though the usefulness of coagulation markers in predicting
thrombosis during chemotherapy and/or hormonal treatment in
patients with cancer is not established, it is well known that some
genetically based abnormalities of coagulation are generally
associated with an increased risk for VTE [11]. Inherited resistance
to activated protein C is a prothrombotic condition resulting from
a gain-of-function mutation of coagulation factor V, commonly
referred to as factor V Leiden. A single guanine (G) to adenine (A)
missense mutation in the factor V gene at nucleotide 1691 sub-
stitutes G for A, resulting in a mutant protein resistant to the anti-
coagulant action of activated protein C [12]. This mutation is the
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most common inherited risk factor for VTE, with a prevalence of
∼5% in the general Caucasian population and 20–50% among
patients with VTE. The estimated risk of DVT in heterozygous
carriers of the mutation is five- to 10-fold higher, whereas for
homozygous carriers is 80- to 100-fold higher, than in non-carriers
[11]. Another prothrombotic gain-of-function mutation has been
identified in the 3′ untranslated region of the prothrombin gene
(the substitution of A for G at position 20 210). The mutant allele
is present in ∼2% of the general population and increases the risk
of DVT by three- to five-fold [11]. Since the etiology of VTE is
multifactorial [13], and considering that factor V Leiden and the
G20210A prothrombin mutation are the most common inherited
risk factors for VTE, we hypothesized a role for these mutations in
causing catheter-related DVT in patients with advanced cancer
treated with chemotherapy. With this background, this case–control
study was carried out in patients with locally advanced or meta-
static breast cancer who developed DVT during continuous infusion
of fluorouracil-based chemotherapy through an implanted CVC.
Patients and methods
Patients
Between January 1999 and February 2001, we investigated a cohort of 300
consecutive women with locally advanced or metastatic breast cancer treated
at a single institution with chemotherapy administered continuously through a
totally implantable CVC. Among them, 182 were identified by retrospective
scrutiny of the medical charts and 118 were prospectively enrolled and
followed up. The study protocol was approved by the Ethical Scientific Com-
mittee of the European Institute of Oncology. Written informed consent was
obtained from all patients. A nested case–control study was carried out, taking
as cases women with an objectively documented first episode of catheter-
related subclavian vein thrombosis (CRT). For each case we enrolled as
controls two women without DVT, matched with cases for age (±5 years),
identical chemotherapy, stage of disease and prognostic features (i.e. extent
and site of metastases, pT size, pN degree of involvement, grade, Ki67 expres-
sion, vascular invasion, steroid hormone receptor expression and HER2/neu
overexpression in the tumor). Patients who received previous chemotherapy
and/or hormonal therapy, those with previous episodes of VTE, and those with
congenital deficiencies of antithrombin, protein C and protein S, as well as
antiphospholipid antibodies, were not eligible for the study. No patient
received anticoagulant or antiplatelet aggregation prophylaxis. The diagnosis
of catheter-related DVT was made by color Doppler ultrasonography of the
internal jugular and subclavian veins when indicated by clinical signs such as
the appearance of arm/facial venous engorgement, swelling, redness and/or
pain. When clinical signs persisted and ultrasound examination was negative,
the latter was repeated after 5–7 days. When symptoms suggestive of pul-
monary embolism developed, radionuclide lung scanning was performed. In
patients with a documented thrombus, the catheter was removed and heparin
was given intravenously for at least 5 days, followed by oral anticoagulant
therapy with warfarin for a period of at least 3 months.
Insertion and maintenance of Port-A-Cath®
A single type of port constructed of titanium and silicone rubber (Dome
Port™; Bard Inc., Salt Lake City, UT, USA), attached to 9.6-F silastic open-
ended catheter tubing, was implanted in the operating room under fluoroscopic
control by the same experienced staff of surgeons using maximal sterile-barrier
precautions. A standard introductory percutaneous subclavian approach was
used, consisting of the direct puncture of a subclavian vein, introduction of a
guide wire, radiological confirmation of correct wire position, dilatation of the
introductory route, creation of a subcutaneous tunnel and introduction of the
catheter with the tip positioned in the superior vena cava. The patients received
local anesthesia with no additional intravenous sedation; a single dose (2 g) of
cefazoline sodium was given intravenously 15 min before implantation. Post-
operative chest radiography was performed routinely to detect inadvertent
pneumothorax and to confirm correct catheter placement. To prevent clot
formation and catheter blockage, implanted ports were flushed with 20 ml of
normal saline and then filled with sterile, heparinized saline after each infusion
of medication or blood withdrawal (5 ml of a solution containing 50 IU/ml). If
the port remained unused for a long time, the heparin lock was changed once
every 21 or 28 days. This maintenance program was carried out on an out-
patient basis by a experienced nurses.
Genetic studies
Blood was collected from the antecubital vein without venous stasis using
a Vacutainer PrecisionGlide™ needle 0.8 × 38 mm into four 3.15 ml
Vacutainer® tubes containing 0.129 M sodium citrate. The first 5 ml were dis-
carded. Citrated platelet-poor plasma was prepared using two centrifugation
steps: 5 min at 2150 g at room temperature and 10 min at 11 000 g at 4°C. The
blood samples were processed within 30 min of collection. The plasma sam-
ples were stored at –70°C in aliquots of 500 µl until analysis. Analyses for
G1691A factor V and G20210A prothrombin were performed in all patients.
Genomic DNA was extracted from white blood cells using the NucleoSpin
Blood L kit (Macherey-Nagel, Oensingen, Switzerland), according to the
manufacturer’s instructions. Analyses were performed on blinded samples.
The physician was not aware of the mutation status. In addition, technicians
performing assays were unaware of the patient’s status with respect to CRT
and the ultrasound technicians were blinded to the genetic results.
Genotypes were determined by PCR and hybridization with allele-specific
oligonucleotides. The allele specific oligonucleotide for factor V A1691 was
3′-TGGACAGGCAAGGAATAC-5′, and for factor V G1691 3′-GGACAG-
GCGAGGAATAC-5′. The prothrombin fragment of 230 bp was cleaved by
HindIII in case the G→A mutation was present, and yielded two smaller frag-
ments of 190 and 40 bp. Dots were visualized on radiograph films (DuPont,
Brussels, Belgium) after overnight radiation. Some samples were retested by
restriction fragment-length polymorphism.
Statistical analysis
Fisher’s exact test was used to compare genotypes in cases and controls. The
different distribution of individual characteristics in cases and controls was
tested using the Fisher’s exact test for categorical variables and the non-
parametric Mann–Whitney U-test for continuous variables. Unconditional
logistic regression analysis was used to estimate the age-adjusted odds ratio as
a measure of thrombosis risk in carriers of factor V Leiden or prothrombin
mutation compared with non-carriers. All tests were two-sided and signifi-
cance referred to P ≤0.05.
Results
The main characteristics of the study population are reported in
Table 1. From the cohort of 300 eligible women with locally
advanced or metastatic breast cancer, 25 (8.3%) who developed
CRT and 50 controls were included in this nested case–control
study. No case of pulmonary embolism was diagnosed. Age distri-
bution, menopausal status, previous surgery and type of chemo-
therapy were similar in cases and controls. The number of cycles
was greater in controls (median six) than in cases (median three)
(P <0.001). Five cases and two controls were heterozygous carriers
of G1691A factor V, giving a prevalence of 20% [95% confidence
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interval (CI) 9% to 39%] and 4% (95% CI 1% to 14%), respectively
(P = 0.04). The age-adjusted odds ratio for catheter-related DVT
was 6.1 (95% CI 1.1–34.3). The median time elapsed from start of
chemotherapy to thrombosis was not significantly different
between those with (31 days) and without (43 days) the mutation
(P = 0.6). Only one case and no control carried the G20210A
mutation in the prothrombin gene (P = 0.30). The age-adjusted
odds ratio for the presence of either mutation was 7.6 (95% CI
1.4–41.0).
Discussion
To our knowledge, this is the first study evaluating the role of the
prothrombotic, gain-of-function mutations of the factor V and
prothrombin gene as risk factors for CVC-related DVT in a homo-
geneously treated group of patients with breast cancer. The study
aimed to identify features that would help to predict thrombotic
complications. It shows that in patients who develop catheter-
related DVT while receiving continuous infusion 5-fluorouracil-
based chemotherapy for advanced breast cancer, the prevalence of
factor V Leiden is five times higher than in those without throm-
bosis, giving a six-fold greater relative risk.
The type of treatment used (including 5-fluorouracil continuous
infusion) is highly effective in controlling disease and its related
symptoms, with a rather low burden of subjective side effects. In a
previous study on 182 breast cancer patients treated with this type
of chemotherapy [14], we observed a 7.7% incidence of VTE,
similarly distributed among patients with early/locally advanced
disease or overt metastases. Thrombosis associated with a CVC is
a serious complication in these patients, and is associated with
significant morbidity (pain, edema) and some risk of pulmonary
embolism. The impact of thrombosis on continuation of treatment
was clear, because the number of chemotherapy courses in cases
(median three) was lower than in controls (median six) (P <0.001),
owing to catheter removal and discontinuation of therapy in all
patients with catheter-related DVT.
Studies similar to ours were previously carried out mostly in
patients with hematological malignancies. Fijnheer et al. [15],
who investigated the occurrence of thrombosis associated with
CVCs in 277 consecutive patients receiving allogenic bone
marrow transplantation, found that of 13 patients heterozygous for
factor V Leiden, seven (54%) had a subclavian vein thrombosis,
while only 9% of the patients without factor V Leiden had this
complication (relative risk 7.7; 95% CI 3.3–17.9) On the other
hand, Sifontes et al. [16] found no increased risk of thrombosis
related to factor V Leiden in children with various types of cancer,
even though the only child heterozygous for the factor V Leiden
mutation had thrombosis in association with an indwelling venous
catheter. Rees et al. [17] found no association between thrombosis
and factor V Leiden in a small cohort of patients with acute pro-
myelocytic leukaemia. Finally, no association between DVT and
the presence of inherited prothrombotic markers was found in 60
children with a CVC and acute lymphoblastic leukemia treated
with the prothrombotic agent L-asparaginase [18].
This study has some limitations. First, the confidence interval of
the relative risk of thrombosis is wide, owing to the small number
of patients included in the analysis. Secondly, patients were not
routinely screened for CRT; therefore, there is the possibility that
some of the controls might have had CRT and were in fact cases.
Finally, a selection bias for living patients able to sign the
informed consent might have occurred, since part of our study
population was retrospectively identified through medical charts.
However, given the relatively low rate of embolization of CVC-
related vein thromboses, the probability of having missed fatal
cases is low. In addition, all breast cancer patients who received
chemotherapy between January 1999 and February 2001 and
developed a symptomatic CRT during treatment have been evalu-
ated in this study.
The consensus recommendation for the prevention of VTE in
patients with long-term indwelling CVC includes the prophylactic
use of low-dose warfarin (1 mg a day) or low molecular weight
heparins [19]. Results of two randomized trials of these treatments
on the prevention of thromboembolic complications in patients
with cancer and CVC showed some benefit, but failed to modify
clinical practice [20, 21]. The results of more recent studies show
that the incidence of CRT has decreased substantially over the
past decade, probably due to improved quality and handling of
catheters. Hence, the benefit of primary prophylactic anticoagulation
remains questionable [22, 23]. Moreover, a recent retrospective
study revealed a high incidence of excessive anticoagulation
(expressed by INR elevation) when minidose warfarin was given
along with an intermittent dose of fluorouracil-based infusion
chemotherapy [24]. The identification of a subgroup of patients
with cancer at high risk for DVT would be a reasonable strategy to
avoid medical devices that enhance the risk of thrombosis, or,
more likely, to consider the implementation of primary antithrom-
botic prophylaxis. Our study suggests that factor V Leiden carriers
with advanced or metastatic breast cancer are at higher risk of
developing catheter-related DVT during chemotherapy. We do
not advise genetic testing for all patients with breast cancer receiving
continuous infusion chemotherapy through a totally implantable
CVC, because the number of patients to be tested to avoid few
Table 1. Individual characteristics of the study and control groups
aMedian and interquartile range (25th and 75th percentile).
Cases 
(n = 25)
Controls 
(n = 50)
P value
Age (years)a 51 (46–55) 50 (43–54) 0.4
Menopausal status [n (%)]
Premenopausal 11 (44) 25 (50) 0.8
Postmenopausal 14 (56) 25 (50)
Tumor stage [n (%)]
Localized (locally advanced) 15 (60) 29 (59) >0.9
Metastatic 10 (40) 21 (41)
Number of cyclesa 3 (2–5) 6 (4–6) <0.001
Surgery [n (%)]
Yes 24 (96) 48 (98) >0.9
No 1 (4) 1 (2)
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episodes of VTE is likely to confer little cost-effectiveness to this
strategy. However, it is reasonable to offer testing to patients with
a positive history of VTE (even when not cancer-related). In
patients so identified, there could be two options: the implemen-
tation of antithrombotic prophylaxis or the choice of alternative
cytotoxic treatments not requiring continuous infusion and the
implantation of CVC. A validation of our findings in a prospective
study is warranted.
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